Jagiellonian University Repository

Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs : results of the GO-MORE study in the Polish population

pcg.skipToMenu

Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs : results of the GO-MORE study in the Polish population

Show full item record

dc.contributor.author Jekla, Sławomir pl
dc.contributor.author Batko, Bogdan pl
dc.contributor.author Korkosz, Mariusz [SAP20001201] pl
dc.contributor.author Majdan, Maria pl
dc.contributor.author Kwiatkowska, Brygida pl
dc.contributor.author Dankiewicz-Fares, Iwona pl
dc.contributor.author Sobiecki, Jerzy M. pl
dc.contributor.author Samborski, Włodzimierz pl
dc.date.accessioned 2020-01-17T09:57:42Z
dc.date.available 2020-01-17T09:57:42Z
dc.date.issued 2018 pl
dc.identifier.issn 1899-5276 pl
dc.identifier.uri https://ruj.uj.edu.pl/xmlui/handle/item/143029
dc.language eng pl
dc.rights Key words: methotrexate, rheumatoid arthritis, golimumab, disease-modifying antirheumatic drugs *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/pl/legalcode *
dc.title Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs : results of the GO-MORE study in the Polish population pl
dc.type JournalArticle pl
dc.description.physical 493-499 pl
dc.description.volume 27 pl
dc.description.number 4 pl
dc.description.points 15 pl
dc.identifier.doi 10.17219/acem/68737 pl
dc.identifier.eissn 2451-2680 pl
dc.title.journal Advances in Clinical and Experimental Medicine pl
dc.language.container eng pl
dc.affiliation Wydział Lekarski : Zakład Reumatologii i Balneologii pl
dc.subtype Article pl
dc.rights.original CC-BY-NC-ND; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0 pl
dc.identifier.project ROD UJ / OP pl
dc.cm.id 88425
dc.cm.date 2020-01-07
.pointsMNiSW [2018 A]: 15


Files in this item

This item appears in the following Collection(s)

Key words: methotrexate, rheumatoid arthritis, golimumab, disease-modifying antirheumatic drugs Except where otherwise noted, this item's license is described as Key words: methotrexate, rheumatoid arthritis, golimumab, disease-modifying antirheumatic drugs